Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Research Analysts' Recent Ratings Updates for Crinetics Pharmaceuticals (CRNX)
05:36am, Friday, 01'st May 2020
Crinetics Pharmaceuticals (NASDAQ: CRNX) recently received a number of ratings updates from brokerages and research firms: 4/28/2020 – Crinetics Pharmaceuticals was downgraded by analysts at Zacks I
Bank of New York Mellon Corp Boosts Holdings in Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)
08:38am, Sunday, 26'th Apr 2020
Bank of New York Mellon Corp lifted its stake in Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 3.4% in the 4th quarter, HoldingsChannel reports. The firm owned 35,847 shares of the company’s stock
Crinetics Pharmaceuticals (NASDAQ:CRNX) Lifted to Buy at Zacks Investment Research
07:34am, Sunday, 26'th Apr 2020
Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage
Head-To-Head Review: Crinetics Pharmaceuticals (NASDAQ:CRNX) and BioXcel Therapeutics (NASDAQ:BTAI)
06:28am, Saturday, 25'th Apr 2020
Crinetics Pharmaceuticals (NASDAQ:CRNX) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the st
Biotechs Mersana Therapeutics, Crinetics See Activist Action
12:30am, Saturday, 25'th Apr 2020
Bain Capital Life Sciences plans to take an active role with Mersana, while Perceptive Advisors increased its stake in Crinetics.
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Increased to Hold at BidaskClub
09:42am, Thursday, 23'rd Apr 2020
Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Thursday, BidAskClub repor
Alliancebernstein L.P. Acquires 600 Shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)
08:22am, Wednesday, 22'nd Apr 2020
Alliancebernstein L.P. boosted its holdings in shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 5.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Ex
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Rating Lowered by Zacks Investment Research
05:48am, Wednesday, 22'nd Apr 2020
Crinetics Pharmaceuticals (NASDAQ:CRNX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports. According to
What Kind Of Shareholder Owns Most Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock?
11:19am, Tuesday, 21'st Apr 2020
The big shareholder groups in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) have power over the company. Large...
Daily Insider Ratings Round Up 4/17/20
12:35pm, Monday, 20'th Apr 2020
Tables of the top insider purchases and sales filed with the SEC on 4/17/20, based on dollar value. Dollar values often do not equate with significance when it
Insider Selling: Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Major Shareholder Sells 84,598 Shares of Stock
09:54am, Sunday, 19'th Apr 2020
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) major shareholder Vivo Capital Viii, Llc sold 84,598 shares of the stock in a transaction dated Friday, April 17th. The stock was sold at an average price o
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Major Shareholder Vivo Capital Viii, Llc Sells 215,810 Shares
08:18am, Sunday, 19'th Apr 2020
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) major shareholder Vivo Capital Viii, Llc sold 215,810 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The stock wa
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Expected to Announce Earnings of -$0.63 Per Share
07:02am, Sunday, 19'th Apr 2020
Wall Street brokerages expect Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) to announce earnings of ($0.63) per share for the current quarter, according to Zacks. Zero analysts have made estimates for C
Zacks Investment Research Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to "Buy"
06:06am, Sunday, 19'th Apr 2020
Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday, Zacks.com reports. The firm curren
Cubist Systematic Strategies LLC Buys 2,922 Shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)
09:06am, Saturday, 18'th Apr 2020
Cubist Systematic Strategies LLC grew its stake in shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 164.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 4,700 shares of the
